Our look is new. Our purpose is the same. Learn more about our brand evolution.
Dyne Therapeutics, a Waltham, Massachusetts, biopharmaceutical company, announced yesterday that it is accelerating its FSHD therapy development program. Here is their press release: Dyne to evaluate therapies targeting genetic cause […]
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results May 13, 2020 at 7:00 AM EDT CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), […]
The FSHD Society is partnering with researchers on an important study of the impact of COVID-19 on the muscular dystrophy community. Please read this letter from Dr. Rabi Tawil and […]
This May 5, the FSHD Society is participating in #GivingTuesdayNow. This is a global day of giving and unity that arose as an emergency response to the unprecedented need caused […]